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Abstract: The landscape of somatic copy-number alterations (SCNAs) affecting long non-coding
RNAs (lncRNAs) in human cancers remains largely unexplored. While the majority of lncRNAs
remain to be functionally characterized, several have been implicated in cancer development and
metastasis. Considering the plethora of lncRNAs genes that have been currently reported, it is
conceivable that many more lncRNAs might function as oncogenes or tumor suppressor genes.
We devised a strategy to detect focal lncRNA SCNAs using a custom DNA microarray platform
probing 10,519 lncRNA genes. By screening a panel of 80 cancer cell lines, we detected numerous
focal aberrations targeting one or multiple lncRNAs without affecting neighboring protein-coding
genes. These focal aberrations are highly suggestive for a tumor suppressive or oncogenic role of
the targeted lncRNA gene. Although functional validation remains an essential step in the further
characterization of the involved candidate cancer lncRNAs, our results provide a direct way of
prioritizing candidate lncRNAs that are involved in cancer pathogenesis.
Keywords: lncRNA; long non-coding RNA; array CGH; somatic copy-number alterations
1. Introduction
The cancer genome is marked by large numbers of genetic and non-genetic alterations. The greater
majority of those are somatic. Only a small fraction of the somatic mutations, the so-called driver
mutations, contribute to cancer development by activating or inactivating specific cancer genes.
The remainder are passenger mutations that do not confer a growth advantage, but were acquired at
some point during cancer cell proliferation [1]. Differentiating between driver and passenger mutations
is one of the biggest challenges in the quest for new cancer genes and putative therapeutic targets.
While somatic alterations can be as small as a single nucleotide substitution, insertion or deletion,
somatic copy-number alterations (SCNAs) affect the largest fraction of the genome [2]. In some
cases, SCNAs affect entire or partial chromosome arms. The ability to detect these genetic/genomic
alterations using (molecular) cytogenetic methods has made large SCNAs historically the best studied
cancer-associated genetic alterations. Many well-known oncogenes and tumor suppressor genes
have been initially identified as targets of recurrent genomic amplifications or deletions, respectively.
Notable examples are tumor suppressor genes PTEN [3] and RB1 [4], and oncogenes HER2 (ERBB2) [5]
Non-coding RNA 2018, 4, 21; doi:10.3390/ncrna4030021 www.mdpi.com/journal/ncrna
Non-coding RNA 2018, 4, 21 2 of 11
and the MYC-family of transcription factors [6,7]. The resulting diagnostic and therapeutic successes
have made cancer SCNAs the subject of many studies. Additionally, the advent of array comparative
genome hybridization (array CGH) platforms that enable the robust identification of small SCNAs
have greatly improved our knowledge of the cancer genome [8–10].
As cancer genetics until now mainly focused on protein-coding genes, not much is known about
SCNAs that affect non-coding RNA genes in cancer. In recent years, our knowledge on the non-coding
genome has expanded enormously. This is especially the case for the class of long non-coding RNAs
(lncRNAs), consisting of genes with transcripts that are larger than 200 nucleotides that do not
encode proteins. In the past five years, tens of thousands of human lncRNAs have been reported and
catalogued, making this the largest genetic class in the human genome [11]. While the bulk of lncRNAs
remains to be functionally annotated, they have been implicated in many important normal cellular
processes such as dosage compensation [12], chromatin remodeling [13], and cell differentiation [14];
when deregulated, they play a role in disease as well, including cancer [15].
The discovery of cancer-associated lncRNAs such as HOTAIR [16], MALAT1 [17], and PVT1 [18]
uncovered an important role for lncRNAs in oncogenesis. The reason for the current hiatus in
our knowledge on lncRNA SCNAs is the fact that the majority of lncRNA annotations are very
recent. Most commercially available platforms or reference databases are based on older genomic
annotations (with no probes for lncRNAs, or probes for as-yet unannotated lncRNAs), or lncRNAs
are simply overlooked in the data analysis. Indeed, recurrent SCNAs outside of protein-coding
regions have been reported [2,19]. To overcome this problem, existing DNA microarray platforms have
been repurposed, and probe content has been reannotated with current lncRNA annotation [20,21].
One such effort resulted in the discovery of the oncogenic focally amplified lncRNA on chromosome 1
(FAL1) [21,22] and the ovarian adenocarcinoma amplified lncRNA (OVAAL) [23] lncRNAs, which are
implicated in epithelial and ovarian cancers. While the potential of this approach lies in its ability
to make use of the large amount of publically available DNA microarray data, the platforms used
have several disadvantages for the discovery of putative cancer-associated lncRNAs. Whole cancer
genome sequencing has the potential in principle to circumvent these limitations, but the method is
still relatively expensive and challenging in terms of data analysis. Consequently, public databases
(e.g., The Cancer Genome Atlas (TCGA, National Cancer Institute, Bethesda, MD, USA)) are mainly
populated with targeted exome sequencing datasets, again focusing on protein-coding genes. Lastly,
while shallow whole cancer genome sequencing is a cost-effective method to detect copy number
variations, its coverage is limited to large events.
Here we present a targeted and cost-effective approach to identify focal lncRNA SCNAs that is
based on a custom DNA microarray covering 10,519 lncRNA genes and their flanking protein-coding
genes. We show that this platform has the ability to detect focal aberrations that only affect lncRNA
exons, and it does not encompass their flanking protein-coding genes. By analyzing the DNA of 80 cell
lines from 11 cancer types, we reveal that lncRNAs are frequently targeted by focal aberrations in
human cancer. In addition, we have generated a dataset with putative oncogenic and tumor suppressor
lncRNAs for future functional studies.
2. Results
2.1. A Targeted Platform to Detect Focal Copy Number Changes in lncRNA Genes
Long non-coding RNAs are underrepresented on commercial array CGH platforms, and the mean
chromosomal distance between the probes on these arrays makes them unsuitable for detecting small
aberrations that only involve (part of) a single lncRNA gene (Figure S1).
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In order to detect small and focal SCNAs that only affect lncRNA exons, we designed a
custom 180K CGH array covering intergenic lncRNA exons, and the nearest exons of their flanking
protein-coding genes. To this purpose, we constructed a database with 52,324 non-redundant exons
derived from all transcripts listed in LNCipedia 1.0 (Figures S2 and S3) [11]. The database was
subsequently extended with protein-coding gene annotation from Ensembl (EMBL-EBI, Wellcome
Genome Campus, Hinxton, UK). Next, we designed probes using the genomic sequence of the lncRNA
exons, and the two nearest exons of the flanking protein-coding genes. By removing duplicate probes
in overlapping exons and selecting additional probes for transcripts with fewer exons, we were able to
cover the majority (94%) of the transcripts with at least 10 probes (Figure S4). Only 1.2% of lncRNAs
could not be covered by any probe. For 95% of the lncRNA transcripts, we succeeded in designing two
probes for each flanking protein-coding exon.
To assess the quality of our custom array CGH platform, we compared the profiles for 60 cancer cell
lines (NCI-60 subset) to publically available profiles of two different array CGH platforms. The average
log ratio in 1 Mb bins was calculated and correlated between the different platforms. These correlations
were compared with correlations among unrelated cell lines (Figures S5 and S6). Correlation between
the same cell lines across the different platforms was high (median Pearson’s correlation = 0.70),
validating the quality of our profiles. As expected, the cell lines derived from the same individual (such
as National Cancer Institute (NCI)/ADR-RES and OVCAR-8) were also highly correlated (Pearson’s
correlation = 0.74). In addition, this analysis revealed problems with two DNA samples (HCT-15 and
CAKI-1), as the obtained profiles showed poor correlations with publically available profiles. This poor
correlation remained unresolved after repeating the hybridization. As such, results from these two cell
lines should be interpreted with care.
2.2. Frequent Focal lncRNA Copy Number Alterations in Cancer Cell Lines
To explore focal lncRNA SCNAs in cancer, we analyzed DNA from 80 cancer cell lines covering
11 cancer types with our custom DNA microarray (Table 1). An extensive filter was performed on the
resulting segments to shortlist focal lncRNA SCNA alterations. To be considered a lncRNA SCNA,
a segment should (1) overlap with the exonic lncRNA sequence; (2) not be contained within known
segmental duplications; (3) overlap with at most three known variants, and (4) have an absolute
average log-ratio that is larger than 1.5 (reflecting homozygous deletions and gene amplifications).
In the case of an amplification, an additional requirement was that the segment included the entire
transcript. Finally, to withhold a focal SCNA (5), the segment cannot overlap any of the flanking
protein-coding gene exons. Using these settings, 173 focal SCNAs affecting 136 lncRNAs in at least
one cell line were identified (Figure 1, Table S1). The majority of these lncRNAs (111) were affected in
a single cell line, 16 are affected in two cell lines, 7 in three cell lines, one in four cell lines, and one
in five cell lines. By confining the relative difference in log-ratio between the segment covering the
lncRNA and the segment covering the flanking protein-coding genes, it was possible to retain the
superimposed SCNAs (for instance, a large hemizygous deletion that contains a smaller homozygous
deletion). A more stringent subset of 76 lncRNA SCNAs was obtained if we required that the flanking
protein-coding gene did not show any copy number change (Figure S7, Table S2). This stringent
set excluded stacked events, e.g., a homozygous deletion in a larger heterozygous deletion that
encompasses one of the flanking protein-coding genes.
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Figure 1. Overview of the long non-coding RNA (lncRNA) genes affected by focal somatic copy-number
alterations (SCNAs) after extensive filtering. Red represents the copy number loss (log-ratio < 1.5)
in that cell line, while blue corresponds to copy number gain (log-ratio > 1.5). Dark red and blue
correspond to copy number changes with absolute log-ratios of above 2.5.
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Table 1. Overview of the cell line panel and the cell line origins.
Cancer Type # Cell Lines Origin
Breast 6 MCF7, MDA-MB-231, HS578T, BT-549, T47D, MDA-MB-468 NCI
CNS 6 SF-268, SF-295, SF-539, SNB-19, SNB-75, U251 NCI
Colon 7 COLO205, HCC-2998, HCT-116, HCT-15, HT29, KM12, SW-620 NCI
Leukemia 6 CCRF-CEM *, HL-60, K-562, MOLT-4 *, RPMI-8226, SR NCI
Melanoma 9 LOXIMVI, MALME-3M, M14, SK-MEL-2, SK-MEL-28, SK-MEL-5,UACC-257, UACC-62, MDA-MB-435 NCI
Non-small cell lung 9 A549, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23,NCI-H322M, NCI-H460, NCI-H522 NCI
Ovarian 7 IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8,SK-OV-3, NCI-ADR-RES NCI
Prostate 2 PC-3, DU-145 NCI
Renal 8 786-0, A498, ACHN, CAKI-1, RXF-393, SN12C, TK-10, UO-31 NCI
T-cell acute
lymphoblastic leukemia 8
Jurkat-DSMZ, ALL-SIL, DND-41, HPB-ALL, TALL-1, LOUCY,
MOLT-16, PEER DSMZ
Neuroblastoma 12 CLB-GA, IMR-32, NB-1, NGP, N206, SHEP, SH-SY5Y, SK-N-SH,SK-N-BE-2c, CHP-134, SK-N-AS, CHP-902R CMGG
11 types 80
* MOLT-4 and CCRF-CEM are T-cell acute lymphoblastic leukemia cell lines in the NCI60 panel. CNS = central
nervous system, NCI = National Cancer Institute.
2.3. Quantitative Polymerase Chain Reaction Confirms the Majority of Focal Aberrations
We devised a unique strategy to validate the selected focal lncRNA SCNAs using quantitative
polymerase chain reaction (qPCR). Assays were designed by targeting the genomic locus of the
aberration and the nearest exons of the flanking protein-coding genes. By comparing the Cq value of
the lncRNA locus and the flanking coding exons, we could accurately assess the difference in copy
number between the two. Using this strategy, we evaluated 88 events (Figure 2). For 66 of these (75%),
an altered copy number status compared to at least one of the two flanking assays could be confirmed,
of which 43 (49%) showed an expected relative difference in Cq values with both flanking assays,
and they were thus validated as focal aberrations. The validation rate was higher for the amplifications
than for the deletions (56% and 48%, respectively). The validation rate drastically increased when we
limited our analysis to the subset of segments with an absolute average log-ratio that was larger than
2.5. In that case, 58 out of 64 (91%) events were confirmed to be copy number alterations. The fraction
of confirmed focal aberrations remained similar (53%).
2.4. Most Novel lncRNA Aberrations do not Correspond to Common Somatic Variants
As our custom platform differed considerably from other array CGH platforms, it was not
unlikely that the newly found SCNAs actually comprised uncharted germline copy-number variants
that may exist in a normal population and that do not contribute to cancer. To assess this possibility,
we performed an qPCR experiment for five validated loci on DNA from 192 healthy individuals.
Neither homozygous deletions nor high order amplifications could be detected for any lncRNAs
in any of the samples (Figure S8). Of note: for one lncRNA, heterozygous deletions were found in
12 individuals (6%).
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Figure 2. Quantitative polymerase chain reaction validation of the putative focal SCNAs. The Cq 
value of the aberration is normalized to the Cq value of each of the flanking regions. A copy number 
gain (blue) is considered as confirmed and focal when the relative quantity to both flanking regions 
is higher than one. Similarly, a copy number loss (red) is considered as confirmed and focal when the 
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Figure 2. Quantitative polymerase chain reaction validation of the putative focal SCNAs. The Cq value
of the aberration is normalized to the Cq value of each of the flanking regions. A copy number gain
(blue) is considered as confirmed and focal when the relative quantity to both flanking regions is higher
than one. Similarly, a copy number loss (red) is considered as confirmed and focal when the relative
quantity to both flanking regions is less than one. Red crosses represent Cq values > 35, corresponding
to a homozygous deletion of the flanking regions. Stars represent significant (p-value < 0.05) differences
from one.
3. Discussion
Even though the number of samples that we examined was limited and confined to cell
lines, we were able to detect a large number of SCNAs that specifically affect lncRNA exons.
This suggests that similarly to protein-coding genes, lncRNAs are frequently targeted by SCNAs
in cancer. After rigorous filtering, focusing on novel highly aberrant segments that not encompass
protein-coding genes, we report 136 such events, including 25 that are recurrent. In 76 of the 136 events,
the flanking protein-coding genes are copy number neutral. Since the cancer genome harbors many
large SCNAs, it is important to also consider the events where the flanking protein-coding genes are
not strictly copy number normal, as long as the lncRNA itself is focally affected by a second event
as well.
Our strategy uncovered several cancer-associated lncRNAs. For instance, the known oncogene
PVT1 was detected as a recurrent focal aberration (Figure 1 and Figure S3). PVT1 has been implicated
in several cancer types including gastric cancer [24], ovarian cancer and breast cancer [18]. PVT1
was found to be co-amplified in more than 98% of cancers with a MYC copy number increase [25].
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Our work not only confirms the frequent amplification of PVT1 in cancer, but it also reveals that
PVT1 amplifications can be focal. Another interesting concurrence with previous studies is found in a
large-scale pan-cancer study on SCNAs [19]. Although the authors mainly focus on SCNAs that affect
protein-coding genes and use limited lncRNA annotation, they report one lncRNA, LINC00290, as the
sole member of a frequently deleted region. Our results reveal a recurrent and focal deletion in ovarian
and breast cancer cell lines, suggesting a role in multiple cancer types (Figure 1). Recently, Lanzós and
colleagues identified 15 cancer-driving lncRNAs based on somatic single nucleotide variants (SNVs)
in tumor samples [26]. Our study finds one of those candidates, LINC01505, in a focal deletion in
a neuroblastoma cell line. Furthermore, text mining of the abstracts of publications associated with
the lncRNAs affected by SCNAs in our screen showed a clear enrichment of the word “cancer” (p =
3.608 × 10−14) (Figure 3). This analysis further underscores the potential of our approach to enrich for
cancer-related lncRNAs.
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Figure 3. A comparison word cloud shows strong enrichment of the word “cancer” in abstracts of
publications associated with the lncRNAs affected by SCNAs. The size of each word corresponds to
the deviation of its frequency in abstracts associated with the lncRNAs affected by SCNAs from the
average occurrence frequency. Green words are more prevalent in abstracts on lncRNAs affected by
SCNAs, while orange words are more prevalent in the abstracts on lncRNAs unaffected by SCNAs.
The validation rate determined by qPCR was strongly dependent on the log-ratio cutoff applied to
the segments, with an absolute average log-ratio larger than 2.5 showing high validation rates for the
lncRNA copy number status. The relatively high cutoff is likely to be related to the unique design of our
platform. As the probes are confined to small genomic loci (lncRNA exons) it is not unimaginable that
the observed signal-to-noise ratio is different compared to the typical designs. In addition, qPCR may
not be the most appropriate method to detect hemizygous copy number changes. Even with a stringent
log-ratio cutoff (2.5), only 50% of the events could be confirmed to be truly focal. This suggests that the
limited number of probes on the flanking protein-coding genes is insufficient to define the breakpoints
of the segments in some cases.
Nevertheless, even when taking the validation rate into account, our research finds about
100 lncRNAs affected by focal SCNA. As the majority of these events are likely, no germline
copy-number variants, these SCNAs harbor interesting candidates for further research.
4. Materials and Methods
4.1. A lncRNA Exon Database
Annotation of lncRNA transcripts was obtained from LNCipedia [27] (version 1.0) and stored
in a MongoDB NoSQL database (MongoDB, Inc., New York, NY, USA). Protein-coding transcript
annotation was obtained from Ensembl’s [28] biomart (version 64, September 2011) and stored in the
same format. For every lncRNA transcript, the nearest upstream and downstream protein-coding
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transcripts were determined. To interface with the MongoDB dataset, both perl scripts and mongo
shell scripts were employed. Using MongoDB’s MapReduce functionality, a non-redundant exon
collection was built starting from the collection of non-redundant transcripts.
All lncRNA identifiers used in this work, such as in the tables and captions are based on
LNCipedia 5.2.
4.2. Array Comparative Genome Hybridization Platform Design
An array CGH probe design was performed using Agilent Technologies eArray software (https:
//earray.chem.agilent.com/earray/). A Browser Extensible Data (BED) file of all non-redundant
exons was generated from the exon database and uploaded into eArray for probe design. Since our
criterion to have two probes per exon was initially not met, the exon boundaries were extended and
the corresponding BED files were uploaded as well. The exon boundaries were extended by 100 bp,
300 bp, and 500 bp. In addition, less stringent selection parameters were used for the 500 bp-extended
exon. In this way, five probe datasets were generated and stored in a separate MongoDB collection.
From this collection, two probes per exon (neighborhood) were selected with preference for the
probes closest to the exon. Overlapping transcripts were taken into account, to avoid duplicate
probe selection. For transcripts with fewer than five exons, additional probes were selected until
the transcript was covered by at least 10 probes. For the flanking protein-coding genes, probes were
designed for the two exons closest to the lncRNA. From this set, the two probes nearest to the lncRNA
were selected. The resulting set of 166,417 unique probes was uploaded to eArray and supplemented
with normalization and quality control probe groups recommended by Agilent Technologies. Agilent
Technologies subsequently manufactured the final design in the 4 × 180 K format. The design of the
platform was made publically available through the Gene Expression Omnibus (GEO) website using
the accession number GPL22307.
4.3. Cancer Cell Line DNA and RNA
The NCI provided DNA and RNA samples for all cell lines in the NCI-60 cancer cell line panel.
Neuroblastoma and T-ALL cell lines were available in house; RNA extraction was performed with
the miRNeasy Mini Kit (Qiagen N.V., Venlo, the Netherlands), and DNA extraction with the QIAamp
DNA Mini Kit (Qiagen).
4.4. Array Comparative Genome Hybridization
Four hundred nanograms of genomic DNA was labeled with Cy3-dCTP (GE Healthcare,
Machelen, Belgium) using a Bioprime array CGH genomic labeling system (Thermo Fisher Scientific,
Waltham, MA, USA). In parallel, Kreatech gender-matched controls were labeled with Cy5-dCTP.
Samples were hybridized on the custom array CGH arrays for 40 h at 65 ◦C. After washing, the samples
were scanned at 5 µm resolution using a DNA microarray scanner, G2505B (Agilent Technologies,
Santa Clara, CA, USA). The scan images were analyzed using the feature extraction software 9.5.3.1
(Agilent Technologies). Segmentation was achieved using the circular binary segmentation algorithm
in the DNACopy R package. Visual inspection and creation of the copy number profile plots were
performed with ‘Vivar’ [29]. All of the raw array CGH data files were made publically available
through the GEO website using the accession number GSE85444.
4.5. Segment Analysis and Filtering
Segment position and statistics are stored in a MongoDB collection. A perl script was used to
combine the segment annotation with lncRNA and protein-coding gene annotations in other collections,
and to implement the filtering process. First, only segments that overlapped the lncRNA exons were
retained. Next, segments with an absolute average log-ratio of less than 1.5 were discarded, as were
segments contained within segmental duplications (UCSC genomicSuperDups track), or segments that
overlapped with more than three known variants (database of genomic variants [30]). The absolute
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log-ratio of the nearest segments covering the flanking protein-coding genes should be 0.5 lower than
the segment covering the lncRNA (corresponding to about one copy less). A more stringent subset
of segments was obtained by requiring the absolute log-ratio of the nearest segments covering the
flanking protein-coding genes to be less than 0.35 (copy number neutral).
4.6. Quantitive PCR Validation
Quantitative PCR assays were designed, based on the chromosomal locations of the altered
segment covering the lncRNA and the nearest exons of the two flanking protein-coding genes. Primer
design was performed using Primer3 [31]; primers spanning common single nucleotide polymorphisms
(SNPs) were excluded. The specificity is evaluated using BiSearch [32]. All qPCR reactions were
prepared using Bio-Rad’s SsoAdvanced Universal SYBR Green Supermix in a 5 µL volume (2.5 µL
mastermix, 0.25 µL each of forward and reverse primers (250 nM final concentration) and 2 µL DNA
(5 ng)). Quantitative PCR plates were run on the LightCycler 480 (Roche Life Science, Indianapolis, IN,
USA) using 2 min activation at 95 ◦C, followed by 45 cycles of 5 s at 95 ◦C, 30 s at 60 ◦C, and 1 s at
72 ◦C, and a melt curve analysis.
The calculation of normalized relative quantities was done using qbase+ software version 2.6
(Biogazelle NV, Ghent, Belgium) and the open source statistical environment R (version 3). The Cq
values corresponding to the altered segment were normalized to those corresponding to the flanking
protein-coding genes, and scaled to the control sample (Human Genomic DNA, Roche Life Science,
Indianapolis, IN, USA). Downstream analysis and data visualization was achieved using R and third
party modules (plyr, ggplot2).
4.7. Text Mining
The abstract texts of 2384 curated articles on lncRNAs were obtained from LNCipedia 5.1.
These were subdivided into 127 abstracts on lncRNAs affected by a SCNA in our data and 2257
abstracts on lncRNAs not affected by SCNAs. Next, the abstract text was analyzed in R (version 3.4.4)
using the tidyverse (version 1.2.1), stringi (version 1.2.2), word cloud (version 2.5), and tm (version
0.7-3) packages. In brief: punctuation, stopwords, lncRNA names, and numbers were removed,
and the resulting texts were transformed to a term-document matrix that stored the frequency of
all words in the different groups. The matrix was subsequently used to create a comparison word
cloud. The statistical significance of the enrichment of selected words in the abstracts associated with
lncRNAs affected by a SCNA was tested using Fisher’s exact test.
5. Conclusions
We developed and applied a unique array CGH platform that was capable of detecting small and
focal lncRNA SCNAs. We have screened a panel of 80 cancer cell lines and shortlisted 136 lncRNA
genes with a putative role in cancer. Among this list are several lncRNAs that have been implicated in
cancer, validating our approach. Since the great majority of the lncRNAs on our platform have yet
to be functionally studied, this finding suggests that our research provides many new cancer-related
lncRNA genes. We present a set of lncRNA genes to the lncRNA and cancer research community as
novel candidate cancer lncRNA genes for further functional exploration.
Supplementary Materials: The following are available online at http://www.mdpi.com/2311-553X/4/3/21/s1,
Figure S1: The smallest theoretical segment that covers each lncRNA using the Genome-Wide Human SNP
Array 6.0; Figure S2: Distribution of the number of exons for the lncRNA transcripts in our dataset; Figure S3:
Distribution of the number of transcripts per lncRNA gene (locus); Figure S4: The required number of probes for a
transcript depends on the number of exons; Figure S5: Comparison of the global copy number profiles (averaged in
1 Mb bins) with the publically available profiles of two different array CGH platforms (Agilent 44K and Nimblegen
385k); Figure S6: Complete linkage tree of the cell line based on their global copy number profiles; Figure S7:
Overview of the lncRNA genes affected by focal SCNAs and the copy number normal flanking protein-coding
genes; Figure S8: qPCR validation of five selected loci on 192 DNA samples from healthy individuals; Table S1:
Overview of the lncRNA genes affected by focal SCNAs after extensive filtering and their copy number status in
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the tested cell lines; Table S2: Overview of the lncRNA genes affected by focal SCNAs and the copy number of the
normal flanking protein-coding genes, and their copy number status in the tested cell lines.
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